This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Myocardial infarction (MI)	MicroRNA-126 (miRNA-126)	Tissue culture and mouse studies suggest that increasing miRNA-126 expression may be useful for treating patients following MI. In the mouse studies, 9 of 11 miRNA-126-deficient mice died at 3 weeks post-MI compared with just 3 of 10 wild-type mice. *Ex vivo* cardiac tissue from miRNA-126-deficient mice showed significantly less endothelial sprouting at 6 days than tissue from wild-type controls (p=0.0001). Next steps include developing strategies to increase miRNA-126 signaling, which may aid in post-MI cardiac repair.	Patent application filed for use in angiogenic therapy; licensed to miRagen Therapeutics Inc.	Wang, S. *et al. Dev. Cell*; published online Aug. 11, 2008; doi:10.1016/j.devcel.2008.07.002 **Contact:** Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, Texas e-mail: eric.olson@utsouthwestern.edu